open access

Vol 9, No 3 (2016)
Review paper
Published online: 2016-11-22
Get Citation

Diagnostic approach to type 2B von Willebrand disease

Ksenia Bykowska, Bernardeta Ceglarek
Journal of Transfusion Medicine 2016;9(3):87-100.

open access

Vol 9, No 3 (2016)
REVIEWS
Published online: 2016-11-22

Abstract

Type 2B Von Willebrand disease (VWD) is an inherited bleeding disorder with enhanced VWF
affinity to platelet glycoprotein Iba receptor. It results from mutation within 28 exon of von
Willebrand factor (VWF) that encodes the VWF A1 protein domain. As far as phenotype and
clinical symptoms are concerned 2B VWD resembles another type of bleeding disorder called
platelet-type von Willebrand disease (PT-VWD). In the course of the diagnostic procedure VWD
2B should always be differentation from PT-VWD. It should always be reckoned with in the
case of patients with thrombocytopenia.

Abstract

Type 2B Von Willebrand disease (VWD) is an inherited bleeding disorder with enhanced VWF
affinity to platelet glycoprotein Iba receptor. It results from mutation within 28 exon of von
Willebrand factor (VWF) that encodes the VWF A1 protein domain. As far as phenotype and
clinical symptoms are concerned 2B VWD resembles another type of bleeding disorder called
platelet-type von Willebrand disease (PT-VWD). In the course of the diagnostic procedure VWD
2B should always be differentation from PT-VWD. It should always be reckoned with in the
case of patients with thrombocytopenia.

Get Citation

Keywords

Von Willebrand disease 2B; pathophysiology; genetic basis; clinical and laboratory diagnosis

About this article
Title

Diagnostic approach to type 2B von Willebrand disease

Journal

Journal of Transfusion Medicine

Issue

Vol 9, No 3 (2016)

Article type

Review paper

Pages

87-100

Published online

2016-11-22

Bibliographic record

Journal of Transfusion Medicine 2016;9(3):87-100.

Keywords

Von Willebrand disease 2B
pathophysiology
genetic basis
clinical and laboratory diagnosis

Authors

Ksenia Bykowska
Bernardeta Ceglarek

References (58)
  1. Łopaciuk S. Rozpoznawanie i leczenie choroby von Willebranda. Acta Haematol Pol. 2003; 34(supl. 1): 62–70.
  2. Federici AB, Canciani MT. Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease. Haematologica. 2009; 94(5): 610–615.
  3. Sadler JE, Budde U, Eikenboom JCJ, et al. Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006; 4(10): 2103–2114.
  4. Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev. 2010; 24(3): 123–134.
  5. Mancuso DJ, Tuley EA, Westfield LA, et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry. 1991; 30(1): 253–269.
  6. Bogusz M, Lewandowski K. Choroba von Willebranda od struktury genu do zaburzeń cząsteczki białkowej. Acta Haemat Pol. 2005; 36: 33–43.
  7. Luo GP, Ni B, Yang X, et al. von Willebrand factor: more than a regulator of hemostasis and thrombosis. Acta Haematol. 2012; 128(3): 158–169.
  8. Szántó T, Joutsi-Korhonen L, Deckmyn H, et al. New insights into von Willebrand disease and platelet function. Semin Thromb Hemost. 2012; 38(1): 55–63.
  9. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost. 2003; 1(1): 33–40.
  10. Rayes J, Hommais A, Legendre P, et al. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. J Thromb Haemost. 2007; 5(2): 321–328.
  11. Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987; 69(6): 1691–1695.
  12. Castaman G. Changes of von Willebrand Factor during Pregnancy in Women with and without von Willebrand Disease. Mediterr J Hematol Infect Dis. 2013; 5(1): e2013052.
  13. Pacheco LD, Costantine MM, Saade GR, et al. von Willebrand disease and pregnancy: a practical approach for the diagnosis and treatment. Am J Obstet Gynecol. 2010; 203(3): 194–200.
  14. Dunois-Lardé C, Capron C, Fichelson S, et al. Exposure of human megakaryocytes to high shear rates accelerates platelet production. Blood. 2009; 114(9): 1875–1883.
  15. Poirault-Chassac S, Nguyen KA, Pietrzyk A, et al. Terminal platelet production is regulated by von Willebrand factor. PLoS One. 2013; 8(5): e63810.
  16. Castaman G, Federici AB. Type 2B von Willebrand Disease: A Matter of Plasma Plus Platelet Abnormality. Semin Thromb Hemost. 2016; 42(5): 478–482.
  17. Ruggeri ZM, Pareti FI, Mannucci PM, et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med. 1980; 302(19): 1047–1051.
  18. Ruggeri ZM. Type IIB von Willebrand disease: a paradox explains how von Willebrand factor works. J Thromb Haemost. 2004; 2(1): 2–6.
  19. Casonato A, Gallinaro L, Cattini MG, et al. Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia. Haematologica. 2010; 95(8): 1366–1372.
  20. Castaman G. 2B or not 2B: when VWF is not a good platelet friend. Blood. 2013; 122(16): 2772–2773.
  21. Tosetto A, Castaman G. How I treat type 2 variant forms of von Willebrand disease. Blood. 2015; 125(6): 907–914.
  22. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009; 113(3): 526–534.
  23. Nurden P, Debili N, Vainchenker W, et al. Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. Blood. 2006; 108(8): 2587–2595.
  24. Casari C, Du V, Wu YP, et al. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia. Blood. 2013; 122(16): 2893–2902.
  25. Nurden P, Gobbi G, Nurden A, et al. Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood. 2010; 115(13): 2649–2656.
  26. Thrombocytopathy and type 2B von Willebrand disease. J Clin Invest. 2013; 123: 5004–5006.
  27. Langer F, Obser T, Oyen F, et al. Characterisation of the p.A1461D mutation causing von Willebrand disease type 2B with severe thrombocytopenia, circulating giant platelets, and defective α-granule secretion. Thromb Haemost. 2014; 111(4): 777–779.
  28. Casari C, Berrou E, Lebret M, et al. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3. J Clin Invest. 2013; 123(12): 5071–5081.
  29. Kujovich JL. von Willebrand disease and pregnancy. J Thromb Haemost. 2005; 3(2): 246–253.
  30. Sánchez-Luceros A, Farías CE, Amaral MM, et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost. 2004; 92(6): 1320–1326.
  31. Ozeki M, Kunishima S, Kasahara K, et al. A family having type 2B von Willebrand disease with an R1306W mutation: Severe thrombocytopenia leads to the normalization of high molecular weight multimers. Thromb Res. 2010; 125(2): e17–e22.
  32. Othman M, Favaloro E. Genetics of type 2B von Willebrand Disease: “True 2B,” “tricky 2B,” or “Not 2B.” What Are the Modifiers of the Phenotype? Seminars in Thrombosis and Hemostasis. 2008; 34(06): 520–531.
  33. Lillicrap D. Genotype/phenotype association in von Willebrand disease: is the glass half full or empty? J Thromb Haemost. 2009; 7 Suppl 1: 65–70.
  34. Lillicrap D. Translational medicine advances in von Willebrand disease. J Thromb Haemost. 2013; 11 Suppl 1: 75–83.
  35. Saba HI, Saba SR, Dent J, et al. Type IIB Tampa: a variant of von Willebrand disease with chronic thrombocytopenia, circulating platelet aggregates, and spontaneous platelet aggregation. Blood. 1985; 66(2): 282–286.
  36. Jackson SC, Sinclair GD, Cloutier S, et al. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood. 2009; 113(14): 3348–3351.
  37. Baronciani L, Federici AB, Castaman G, et al. Prevalence of type 2b 'Malmö/New York' von Willebrand disease in Italy: the role of von Willebrand factor gene conversion. J Thromb Haemost. 2008; 6(5): 887–890.
  38. Weiss HJ, Sussman II. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers. Blood. 1986; 68(1): 149–156.
  39. Takimoto Y, Imanaka F. Type 2B Hiroshima: a variant of von Willebrand disease characterized by chronic thrombocytopenia and the presence of all von Willebrand factor multimers in plasma. Int J Hematol. 1999; 70(2): 127–131.
  40. Baronciani L, Federici AB, Beretta M, et al. Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost. 2005; 3(12): 2689–2694.
  41. Casonato A, Sartorello F, Pontara E, et al. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis. Thromb Haemost. 2007; 98(6): 1182–1187.
  42. James PD, Lillicrap D, Mannucci PM. Alloantibodies in von Willebrand disease. Blood. 2013; 122(5): 636–640.
  43. Baaij M, van Galen KPM, Urbanus RT, et al. First report of inhibitory von Willebrand factor alloantibodies in type 2B von Willebrand disease. Br J Haematol. 2015; 171(3): 424–427.
  44. Drouin J, Lillicrap DP, Izaguirre CA, et al. Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis. Am J Clin Pathol. 1989; 92(4): 471–478.
  45. Shigekiyo T, Sekimoto E, Shirakami A, et al. Type 2B-like acquired von Willebrand syndrome. Int J Hematol. 2011; 94(4): 410–412.
  46. Karger R, Weippert-Kretschmer M, Budde U, et al. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome. Blood Coagul Fibrinolysis. 2011; 22(2): 144–147.
  47. Scepansky E, Othman M, Smith H. Acquired von Willebrand syndrome with a type 2B phenotype: diagnostic and therapeutic dilemmas. Acta Haematol. 2014; 131(4): 213–217.
  48. Ulrichts H, Harsfalvi J, Bene L, et al. A monoclonal antibody directed against human von Willebrand factor induces type 2B-like alterations. J Thromb Haemost. 2004; 2(9): 1622–1628.
  49. Ajzenberg N, Depraetere H, Lacombe C, et al. Platelet aggregation induced by a monoclonal antibody to the A1 domain of von Willebrand factor. Blood. 1998; 91(10): 3792–3799.
  50. Hamilton A, Ozelo M, Leggo J, et al. Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study. Thromb Haemost. 2011; 105(3): 501–508.
  51. Othman M, Othman M. Platelet-type Von Willebrand disease: three decades in the life of a rare bleeding disorder. Blood Rev. 2011; 25(4): 147–153.
  52. Zdziarska J, Chojnowski K, Klukowska A, et al. Postępowanie w chorobie von Willebranda. Zalecenia Polskiego Towarzystwa Hematologów i Transfuzjologów 2008. Med Prakt. 2008; 12: 1–24.
  53. Laffan MA, Lester W, O'Donnell JS, et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia. 2004; 10(3): 199–217.
  54. Favaloro EJ. Laboratory identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost. 2006; 32(5): 456–471.
  55. Enayat MS, Guilliatt AM, Lester W, et al. Distinguishing between type 2B and pseudo-von Willebrand disease and its clinical importance. Br J Haematol. 2006; 133(6): 664–666.
  56. Frontroth JP, Hepner M, Sciuccati G, et al. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children. Thromb Haemost. 2010; 104(6): 1158–1165.
  57. Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost. 2008; 34(1): 113–127.
  58. Flood VH, Gill JC, Morateck PA, et al. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood. 2011; 117(6): e67–e74.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Journal of Transfusion Medicine dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl